Briana Ayala, left, with her oncologist, Dr. Ted Laetsch. Dr. Laetsch had Briana’s tumor tested for a TRK fusion and then successfully treated her with larotrectinib. Credit: UT Southwestern Medical Center A first-of-its-kind drug targeting a fused gene found in many types of cancer was effective in 93 percent of pediatric patients tested, researchers at...